Announced
Synopsis
Altaris Capital Partners, an investment firm focused exclusively on the healthcare industry, agreed to acquire the Generic Rx Pharmaceuticals unit of Perrigo, an American Irish–registered manufacturer of private label over-the-counter pharmaceuticals, for $1.5bn. "Given our experience in the pharmaceutical sector and track record of corporate carve-out transactions, we believe we are well-positioned to support the Rx business as it becomes a standalone company focused on its mission of developing and marketing affordable pharmaceutical products," Garikai Nyaruwata, Altaris Managing Director.
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.